Quanterix Business Summary

Quanterix Corporation (QTRX) operates as a life sciences company specializing in ultra-sensitive digital biomarker detection through its proprietary Simoa (Single Molecule Array) technology. The company generates revenue through a hybrid model consisting of high-capital instrument sales (e.g., HD-X and SR-X platforms), a high-margin recurring consumables stream—which accounts for approximately 60% of total revenue—and contract research services via its Simoa Accelerator Laboratory. Following its strategic acquisition of Akoya Biosciences in July 2025, Quanterix has expanded its primary business segments to include both blood-based protein analysis and spatial phenotyping (tissue imaging). The company is currently pivoting toward the clinical diagnostics market, specifically targeting Alzheimer’s disease with its LucentAD multi-marker blood tests. Quanterix competes directly with Bio-Techne, DiaSorin, Meso Scale Discovery (MSD), and Cytek Biosciences, positioning itself as the market leader in ultra-sensitive protein detection with a sensitivity up to 1,000 times greater than conventional analog immunoassays. Quanterix was co-founded in 2007 by Dr. David Walt, a Harvard Medical School professor and co-founder of Illumina, and Nicholas J. Naclerio. The current leadership team is led by President and CEO Everett Cunningham, who assumed the role in January 2026 after serving as Chief Commercial Officer at Illumina and Exact Sciences. The executive suite includes CFO Vandana Sriram, CTO Jerzy Olejnik, and COO Michael Miller. Governance is overseen by Non-Executive Chair Bill Donnelly, a former Mettler-Toledo executive, and Lead Independent Director Jeffrey Elliott. The company is backed by a strong base of institutional investors, including Portolan Capital Management, BlackRock, Vanguard, and William Blair, as it executes a strategic turnaround aimed at achieving cash flow breakeven by late 2026.